The FDA posted to its site the observations made during an inspection of an AstraZeneca (AZN) manufacturing center that was conducted from May 30, 2024 to June 7, 2024, including manufacturing and quality issues that were identified.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- FibroGen China sale ‘shrewd strategic transaction,’ says H.C. Wainwright
- M&A News: AstraZeneca Expands China Footprint With FibroGen Deal
- FibroGen selling FibroGen China to AstraZeneca for $160M
- Soros buys Arthur J. Gallagher, boosts Accenture in Q4
- AstraZeneca: IMFINZI improved event-free survival, OS across MIBC